Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07424625 · ClinicalTrials.gov registry record · Phase 4
A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients
A Phase 4 study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
NCT07424625: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT07424625 is a Phase 4 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 250 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07424625, a Phase 4 study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this research is to determine if two commonly used medications to treat metabolic acidosis in the setting of cardiac surgery, sodium bicarbonate and THAM, are equivalent.
Interventions
- DRUG Sodium bicarbonate
- DRUG Tris-hydroxymethyl Aminomethane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07424625
The ClinicalTrials.gov registry entry for NCT07424625 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium bicarbonate is the first listed.
NCT07424625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07424625 about?
NCT07424625 is a clinical study titled "A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients". The purpose of this research is to determine if two commonly used medications to treat metabolic acidosis in the setting of cardiac surgery, sodium bicarbonate and THAM, are equivalent.
What is the current status of trial NCT07424625?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2026-07. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07424625?
The interventions under investigation include: Sodium bicarbonate (DRUG), Tris-hydroxymethyl Aminomethane (DRUG).
Who is sponsoring clinical trial NCT07424625?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.